Liminal BioSciences is a global biotechnology company that specialises in discovering, developing and commercializing novel small molecule compounds for respiratory, liver and renal diseases. We focus specifically on developing solutions for rare and orphan diseases.
Our expertise in small molecules has enabled a strong late-stage pipeline with potential best-in-class drugs. Our small molecule therapeutics pipeline leverages the discovery of two fatty acid receptors (GPR40 and GPR84) which have been shown to promote tissue regeneration and scar resolution.
Why Invest? Our world-class research and development team are constantly pushing boundaries to make discoveries which help the scientific community better understand rare disease and orphan drug development, especially effecting the liver, kidney and respiratory system.